Contact
Please use this form to send email to PR contact of this press release:
Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy
TO:
Please use this form to send email to PR contact of this press release:
Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy
TO: